American Cancer Society

Visory Health CEO and Founder Susan Lang Named to 2023 Forbes 50 Over 50 List

Retrieved on: 
Tuesday, August 8, 2023
Linda, Inc., BJC HealthCare, Female, Pharmacy, Woman, Thought, Express Scripts, Lang, American Cancer Society, Pharmaceutical industry, Pfizer

ORLANDO, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Visory Health , a prescription discount card and healthcare technology company improving access to affordable medications to everyone, today announces its founder and CEO, Susan Lang , has been honored and recognized on the prestigious Forbes 50 Over 50 list.

Key Points: 
  • ORLANDO, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Visory Health , a prescription discount card and healthcare technology company improving access to affordable medications to everyone, today announces its founder and CEO, Susan Lang , has been honored and recognized on the prestigious Forbes 50 Over 50 list.
  • Lang began her entrepreneurial career as the founder of HooPayz in 2012, then built a leading strategic analytics and technology consulting firm, XIL Health, in 2013.
  • Prior to being named on the 2023 Forbes 50 Over 50 list, Lang was recognized by Inc. last year 100 Female Founder.
  • For more information on Visory Health, visit www.visoryhealth.com or download their app on the Google and Apple Play Store.

Independence Blue Cross and The Colorectal Cancer Alliance Launch 45+ Reasons Campaign to Support Colorectal Cancer Prevention

Retrieved on: 
Tuesday, August 8, 2023
Survival rate, Independence Blue Cross, Perelman School of Medicine at the University of Pennsylvania, Partnership, University, Wellness, Health equity, Cancer, Large intestine, African Americans, Colorectal Cancer Alliance, Penn Medicine Rittenhouse, Black, Organization, Perelman Center for Advanced Medicine, Community Alliance, Incidence, Colorectal cancer, Development, MD, Pennsylvania Department of Aging, Risk, Salix Pharmaceuticals, Child, Colonoscopy, Cycle, Diversity, Radio, University of Pennsylvania Health System, Mortality, American Cancer Society, USPSTF, Willow, Pennsylvania Department of Health, Social media, Disease, Pharmaceutical industry, Mobile phone, Vaccine, Independence, Medicine

PHILADELPHIA, Aug. 8, 2023 /PRNewswire/ -- Independence Blue Cross (Independence) and the Colorectal Cancer Alliance (the Alliance) announced the launch of 45+ Reasons, a campaign to get more than 5,000 Black Philadelphians ages 45-75 screened for colorectal cancer to reduce the significantly higher incidence and mortality rates of Black Americans. The campaign supports the Cycles of Impact initiative launched by Independence and the Alliance in 2022.

Key Points: 
  • To ensure that the colorectal cancer prevention and screening messages reach those most at risk, the Alliance is launching a compelling new awareness campaign called 45+ Reasons.
  • The community engagement, social media, and advertising campaign aims to instill much-needed trust in the healthcare system with fact-based support for colorectal cancer as a preventable cancer.
  • One way we are addressing this is through this partnership with the Colorectal Cancer Alliance to reduce gaps in colorectal cancer screening rates among Black Philadelphians, who are disproportionately impacted by colorectal cancer."
  • "As the largest nonprofit organization solely committed to ending colorectal cancer, the Alliance is uniquely positioned to lead this bold health intervention," said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

Cataldo Ambulance Swing for Hope sets fundraising record to benefit the American Cancer Society

Retrieved on: 
Monday, August 7, 2023
Cataldo Ambulance Service, Vaccination, Cancer, Multimedia, COVID, Golf, EMS, Boston Bruins, Patient, American Cancer Society, Hope Lodge (American Cancer Society), Family, Hospital

SOMERVILLE, Mass., Aug. 7, 2023 /PRNewswire/ -- Swing Fore Hope, Cataldo Ambulance Service's annual charity golf tournament, raised $43,000 for the American Cancer Society's AstraZeneca Hope Lodge in Boston.

Key Points: 
  • SOMERVILLE, Mass., Aug. 7, 2023 /PRNewswire/ -- Swing Fore Hope, Cataldo Ambulance Service's annual charity golf tournament, raised $43,000 for the American Cancer Society's AstraZeneca Hope Lodge in Boston.
  • The Swing Fore Hope tournament raises funds through generous sponsor participation, team registrations, raffle prizes, and an auction.
  • "Being able to support the Hope Lodge and related cancer programs for the past 31 years has been a true passion of mine."
  • It creates a community which provides essential support and nurturing for patients receiving cancer treatment and their families," adds Dennis Cataldo.

United States Women Health Laboratory Testing Research Report 2023-2028: Focus on Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and Diagnostic Testing - ResearchAndMarkets.com

Retrieved on: 
Friday, August 4, 2023
Biotechnology, AIDS, Health, Consumer, Other Health, Oncology, Other Science, Research, Infectious Diseases, General Health, Hospitals, Baby, Maternity, Science, Women, Lymphoma, Disease, Partnership, Prevalence, Accident, HIV, Syphilis, Cancer, Woman, Prenatal development, Infection, Government, Test management, MDS, Pancreatic serous cystadenoma, Hepatitis, MUFG Americas Holdings Corporation, Investment, Syndrome, Anemia, Labcorp, Vertically transmitted infection, Conditional sentence, Growth, Multiple myeloma, American Cancer Society, Leukemia, Trauma, Injury, Dietary supplement, Pharmaceutical industry

The "United States Women Health Laboratory Testing Market by Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and Diagnostic Testing, Region, Competition Forecast & Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Women Health Laboratory Testing Market by Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and Diagnostic Testing, Region, Competition Forecast & Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The United States Women Health Laboratory Testing Market is poised for impressive growth during the period 2024-2028.
  • Moreover, rising cases of aneuploidies and advancements in medical technology are playing significant roles in driving market expansion.
  • Particularly, the rising prevalence of cancer among women has opened up new opportunities for growth in the Women Health Laboratory Testing Market in the United States.

AngioDynamics Completes Enrollment for PRESERVE Clinical Study

Retrieved on: 
Thursday, August 3, 2023
Science, Cardiology, Research, Oncology, General Health, Health, Medical Devices, Clinical Trials, Society, IRE, Partnership, University, Bureau of Oceans and International Environmental and Scientific Affairs, University of Michigan, British Association of Urological Surgeons, Cancer, Quality of life, Ablation, Irreversible electroporation, Death, Incidence, Nanoknife, Regeneration, MD, Patient, Memorial Sloan Kettering Cancer Center, American Cancer Society, Disease, Prostate cancer, Medical imaging

The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).

Key Points: 
  • The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).
  • "The PRESERVE study demonstrates AngioDynamics’ commitment to innovating care delivery,” said Juan Carlos Serna, AngioDynamics Senior Vice President of Clinical and Scientific Affairs.
  • We appreciate the support provided by our PRESERVE study sites and the partnership with the SUO-CTC team in this important effort.”
    Final patient enrollment in the study was initially announced during AngioDynamics’ Fiscal 2023 Fourth Quarter and Full-Year Financial Results conference call on July 12, 2023.
  • The PRESERVE study will have its primary endpoint analysis at 12 months following treatment.

Beyond Meat® Debuts Beyond Stack Burger™, the Brand’s Newest Product Innovation, at Select Kroger Stores Nationwide

Retrieved on: 
Wednesday, August 2, 2023
The American Journal of Clinical Nutrition, Kroger, Taste, American Heart Association, BBQ, Meat, King Soopers, Stanford University, Cholesterol, Beyond Meat, Health, TMAO, Cheese, Research, BYND, Risk, Lettuce, Stanford University School of Medicine, Trial of the century, Hormone, American Journal, LDL, American Cancer Society, Human, Fast food, Ralphs

EL SEGUNDO, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ: BYND), a leader in plant-based meat, today announced the expansion of its burger portfolio with the debut of the company’s newest product innovation, the Beyond Stack Burger™. The delicious new patty is designed to be even closer in taste and texture to beef and is perfect for single, double and triple stacked burgers. The Beyond Stack Burger is debuting as smash-style burgers have grown in popularity, with a 720% increase on menus over the past four years,2 and complements this summer’s launch of the Beyond® Smashable Burger in foodservice, enabling consumers to be able to enjoy irresistible plant-based smash-style burgers both at home and on-the-go.

Key Points: 
  • The delicious new patty is designed to be even closer in taste and texture to beef and is perfect for single, double and triple stacked burgers.
  • This summer, the company launched the newest iteration of Beyond Sausage ®, the #1 selling plant-based dinner sausage in retail,4 with a meatier, juicier taste and texture.
  • For more information on Beyond Meat’s efforts to positively impact human health, visit the Health page.
  • The Beyond Stack Burger is soft launching this week at select Kroger, Ralphs, King Soopers, Fry’s and Smith’s stores.

AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs

Retrieved on: 
Tuesday, August 1, 2023
Oncology, Health, Consumer, Seniors, Clinical Trials, Pharmaceutical, Biotechnology, NIDDK, Marketing, Pain, Medsafe, Adoptive cell transfer, Patient, Carcinoma, Leukemia, Prostate cancer, Disease, Human, EAP, DLBCL, SBIR, Expanded access, Physician, Bone marrow, Research, Lung cancer, Glioblastoma, CUP, Cancer, Type 1, FDA, NCI, Safety, NOD, Desmoplastic small-round-cell tumor, Multimedia, Medicine, CAR, National Cancer Institute, Animal, B-ALL, Otorhinolaryngology, Drug development, Clinical trial, NHL, National Institutes of Health, Medication, CNS, Sale, AVM, American Cancer Society, Nursing, Vaccine, Pharmaceutical industry, Medical device, TCR

Requests for additional information about immunomodulatory AVM0703 and its relatively broad activity against solid tumors and blood cancers can be made by contacting [email protected] .

Key Points: 
  • Requests for additional information about immunomodulatory AVM0703 and its relatively broad activity against solid tumors and blood cancers can be made by contacting [email protected] .
  • “AVM Biotechnology is committed to providing AVM0703 to patients who cannot participate in our enrolling clinical trial.
  • Our team at AVM Biotechnology is dedicated to providing hope to patients and their loved ones.” Theresa Deisher, AVM Biotechnology , Founder and CEO.
  • AVM Biotechnology is a clinical stage company headquartered in Seattle, WA developing immunomodulatory therapies for hematological cancer, infectious and autoimmune diseases.

US Wellness to Offer GRAIL's Galleri®, a Multi-Cancer Early Detection Test, To Its Network of Employers

Retrieved on: 
Tuesday, August 1, 2023
If Memory Serves Us Well, Cancer, Breast, Prostate, Lung, Colon, Organization, GRAIL, Diagnosis, American Cancer Society, Health, Medical imaging, GRAIL (company)

"US Wellness' mission is to provide innovative solutions that inspire people to live healthier, be stronger, and achieve more.

Key Points: 
  • "US Wellness' mission is to provide innovative solutions that inspire people to live healthier, be stronger, and achieve more.
  • "The Galleri multi-cancer early detection test gives us a powerful tool to address cancer risk by identifying cancer early.
  • We believe that Galleri has the potential to help employers reduce cancer claims and address traditional health disparities in cancer detection and screening."
  • In fact, about 71% of cancer deaths are a result of cancers that lack early detection screening.

Francis Medical Receives U.S. FDA Breakthrough Device Designation for Vanquish Minimally Invasive Prostate Cancer Therapy

Retrieved on: 
Tuesday, August 1, 2023
Disease, Cancer, Prostate, OSF Saint Francis Medical Center, Trial of the century, Patient, Prostate cancer, Water, Kidney, Diagnosis, American Cancer Society, Erectile dysfunction, FDA, Urinary incontinence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical imaging, Vanquish

MINNEAPOLIS , Aug. 1, 2023 /PRNewswire/ -- Francis Medical, Inc. , a privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney and bladder cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Vanquish minimally invasive water vapor ablation therapy.

Key Points: 
  • MINNEAPOLIS , Aug. 1, 2023 /PRNewswire/ -- Francis Medical, Inc. , a privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney and bladder cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Vanquish minimally invasive water vapor ablation therapy.
  • To qualify for a Breakthrough Device Designation, a device technology must show that it has the potential to provide a more effective treatment than current standards of care.
  • The therapy is designed to ablate cancer cells while protecting surrounding structures, lessening the likelihood of life-altering side effects common with other prostate cancer treatments.
  • "The goal of Francis Medical is to become the first line therapy of choice for patients with prostate cancer," said Michael Kujak, Francis Medical president and chief executive officer.

Statement from the Prevent Cancer Foundation on updated guidance for colorectal cancer screening from the American College of Physicians

Retrieved on: 
Monday, July 31, 2023
Bleeding, Prevent Cancer Foundation, National Colon Cancer Awareness Month, Fear, Cancer, Large intestine, Risk, Perforated ulcer, Organization, Incidence, Colorectal cancer, National Cancer Institute, Patient, American College of Gastroenterology, Colonoscopy, Confusion, Mortality, American Cancer Society, Transport, American College, NCI, American College of Physicians, ACP, USPSTF, Dietary supplement, Medical imaging, Dairy

Alexandria, Va., July 31, 2023 (GLOBE NEWSWIRE) -- The American College of Physicians (ACP) today issued updated guidance for colorectal cancer screening, recommending asymptomatic, average-risk adults should begin screening for colorectal cancer at age 50.

Key Points: 
  • Alexandria, Va., July 31, 2023 (GLOBE NEWSWIRE) -- The American College of Physicians (ACP) today issued updated guidance for colorectal cancer screening, recommending asymptomatic, average-risk adults should begin screening for colorectal cancer at age 50.
  • The Prevent Cancer Foundation strongly opposes the updated guidance, which goes against the latest evidence-based screening recommendations from the organizations working in the cancer screening space every day.
  • The Prevent Cancer Foundation supports following the guidelines of the USPSTF, the American Cancer Society and American College of Gastroenterology and encourages all adults of average risk to begin colorectal cancer screening at age 45.
  • There are several options available for colorectal cancer screening, and all available colorectal cancer screening methods are safe and can save lives.